Authors
Latest:
Dr. D’Angelo on Emerging Therapies in DLBCLChristopher R. D’Angelo, MD, discusses emerging therapies in diffuse large B-cell lymphoma.
Latest:
Audience Q&A: Emerging Therapeutic Targets in Advanced NSCLCClosing out their discussion on the treatment paradigm of advanced NSCLC, key opinion leaders review emerging targets and ongoing clinical trials.
Latest:
Dr. Huang on Research in ALK+ NSCLCChao H. Huang, MD, FACP, discusses ongoing research around the use of ALK inhibitors for non–small cell lung cancer.
Latest:
Dr. Baron on Contributing Factors for Developing Breast CancerPaul Lawrence Baron, MD, discusses contributing factors for developing breast cancer.
Latest:
Future Perspectives on the Treatment of Desmoid TumorsA panel of oncology experts provides insights into the future outlook for desmoid tumor treatment, discussing anticipated developments in the field.
Latest:
Dr Murray on the Investigation of Prognostic Markers in Cemiplimab-treated NSCLCJoseph Christopher Murray, MD, PhD, discusses the investigation of peripheral myeloid cells as prognostic markers in patients with non–small cell lung cancer treated with cemiplimab.
Latest:
Dr. Abdallah on Interim Efficacy Data on HPN217 in R/R Multiple MyelomaAl-Ola A. Abdallah, MD, discusses interim results from an ongoing phase 1 trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma.
Latest:
Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and LustbergOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
Latest:
Dr. Rettig on the Evolving Use of Triplet Regimens in mHSPCMatthew Rettig, MD, discusses the evolution of triplet therapy within the landscape of metastatic hormone-sensitive prostate cancer, as well as the importance of considering key prognostic factors when utilizing this approach.
Latest:
Discrete Data Are Key to Realizing Electronic Health Records’ Full PotentialElectronic health record systems’ design, usability, and interoperability issues can hinder integration and use.
Latest:
Dr Hunter on the Ongoing Investigation into JAK Inhibitors in MyelofibrosisAnthony M. Hunter, MD, discusses the evolution of JAK inhibitors in myelofibrosis, a topic that was highlighted in a presentation at the 2023 SOHO Annual Meeting.
Latest:
Dr Lee on 3-Year Follow-Up Data From the ROCKstar Trial of Belumosudil in cGVHDStephanie Lee, MD, MPH, discusses 3-year follow-up data from the phase 3 ROCKstar Study of belumosudil in cGVHD.
Latest:
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCLMichael R. Cook, MD, discusses real-world data associated with the utilization of bridging therapy prior to treatment with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.
Latest:
Dr. Bhatt on the Longitudinal Effects of Chronic Diseases in Childhood Cancer SurvivorsNeel S. Bhatt, MBBS, MPH, discusses the longitudinal effects of chronic diseases in childhood cancer survivors.
Latest:
Dr. Wesolowski on the Potential Future Utility of Trastuzumab Deruxtecan in HER2+ Breast CancerRobert Wesolowski, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.
Latest:
UF Health Cancer Center Achieves National Cancer Institute DesignationThe University of Florida Health Cancer Center has received prestigious designation from the National Cancer Institute, or NCI, and joins the ranks of the country’s most distinguished cancer centers, becoming the 72nd in the United States and the only one in North Central Florida.
Latest:
Dr. Pieczonka on the Rationale to Evaluate VERU-111 in mCRPCChristopher Pieczonka, MD, discusses the rationale to evaluate sabizabulin in men with metastatic castration-resistant prostate cancer in the phase 3 VERACITY trial.
Latest:
Advanced Biliary Tract Cancers: Managing Immunotherapy-Related Adverse EventsExpert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.
Latest:
The Evolving Treatment Landscape of Small Cell Lung CancerClosing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.
Latest:
Dr. Contreras on the Use of Surgical Resection in Desmoplastic MelanomaCarlo Contreras, MD, discusses how continued investigations in desmoplastic melanoma could better inform the use of surgical resection in select patients.
Latest:
Dr Arner on the Role of SETD2 Loss in Tumor Growth and Metastasis in ccRCCEmily Arner, PhD, discusses research on the role of SETD2 loss in metastatic clear cell renal cell carcinoma ccRCC.
Latest:
Novel Treatment Approaches Under Investigation for HER2+ mBCJoseph Gligorov, MD, emphasizes the impact of trastuzumab deruxtecan in HER2-positive breast cancer and explores its potential in HER2-low populations, and envisions a future where ADCs and immunotherapy will have a vital role in treatment, particularly in triple-negative breast cancer.
Latest:
Dr. Strati on the Investigation of Immunotherapy Combinations in LymphomaPaolo Strati, MD, discusses several ongoing investigations aiming to improve upon current immunotherapy combinations, highlighting the introduction of novel regimens into the treatment landscape of follicular lymphoma.
Latest:
Dr. Montero on the FDA Approval of Elacestrant in ER+/HER2– Breast CancerAlberto Montero, MD, MBA, CPHQ, discusses the significance of the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.
Latest:
Dr Danish on Post-CAR T-Cell Bridging Radiation Therapy Eligibility in High-Risk NHLAdnan F. Danish, MD, discusses findings from a study evaluating the prevalence of patients with high-risk non-Hodgkin lymphoma who were eligible for bridging radiation therapy prior to receiving CAR T-cell therapy, as well as the outcomes of these patients following CAR T-cell therapy.
Latest:
Dr. Yohe on the Potential to Target RAS Mutations in Pediatric CancersMarielle E. Yohe, MD, PhD, discusses the potential utility of targeting RAS mutations in pediatric cancers.
Latest:
Dr. Harismendy on the Challenges Faced With Molecular Testing in DCISOlivier Harismendy, PhD, discusses the challenge of molecular testing in patients with ductal carcinoma in situ.
Latest:
Dr Pal on the Rationale for Investigating Zanzalintinib in Relapsed/Refractory ccRCCSumanta Kumar Pal, MD, FASCO, discusses the rationale for treating patients with zanzalintinib in relapsed/refractory clear cell renal cell carcinoma.
Latest:
Future Directions in Precision Medicine: An Evolving Treatment LandscapeClosing out their discussion on biomarkers and precision medicine in cancer care, key opinion leaders look toward future evolutions in the oncology landscape.
Latest:
Dr. Searle on Initial Results From the MajesTEC-2 Trial in Multiple MyelomaEmma Searle, MD, discusses early findings from cohort E of the phase 1b MajesTEC-2 trial (NCT04722146) evaluating teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) and lenalidomide (Revlimid) in multiple myeloma.
